leadf
logo-loader
viewVyome Therapeutics Inc.

Vyome Therapeutics expects data from its anti-biotic resistant acne drug end of 2019

Vyome Therapeutics Inc CEO Venkat Nelabhotla sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

Vyome Therapeutics is a clinical stage speciality pharmaceutical company, with platform technologies and a pipeline of drugs for antibiotic-resistant acne and other skin pathogens.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Trident Royalties is 'all about diversification unlike majority of its peers'

Proactive analyst Ryan Long focuses on Trident Royalties (LON:TRR) a newly AIM-listed diversified mining royalty and streaming business. The company aims to provide investors with exposure to a broad range of development and cash-generating mining assets across the base metal, precious metal,...

2 hours, 19 minutes ago

2 min read